CTOs on the Move

Adolor Corporation

www.adolor.com

 
Adolor Corporation is a Exton, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.adolor.com
  • 700 Pennsylvania Dr
    Exton, PA USA 19341
  • Phone: 484.595.1500

Executives

Name Title Contact Details

Similar Companies

Lung Therapeutics

Lung Therapeutics pursues innovative treatments for underserved, life-threatening lung conditions.

Berkeley Lights

Berkeley Lights is a leading digital cell biology company focused on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products for our customers. The Berkeley Lights Platform captures deep phenotypic, functional and genotypic information for thousands of single cells in parallel and can also deliver the live biology customers desire in the form of the best cells. Our platform is a fully integrated, end-to-end solution, comprising proprietary consumables, including our OptoSelect™ chips and reagent kits, advanced automation systems, and application software. We developed the Berkeley Lights Platform to provide the most advanced environment for rapid functional characterization of single cells at scale, the goal of which is to establish an industry standard for our customers throughout their cell-based product value chain. Berkeley Lights` Beacon® and Lightning™ systems and Culture Station™ instrument are for research use only. Not for use in diagnostic procedures.

Advanced Solutions

Advanced Solutions designs and manufactures biofabrication systems for next-generation drug discovery, personalized medicine, and regenerative therapeutics.

Clear Cycle

Clear Cycle is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Morphic Therapeutic

Oral integrin therapies for patients with immunological, fibrotic, neoplastic and vascular diseases. Morphic Tx is joining a three decade quest led by our scientific founder, Tim Springer, who initially discovered the integrin receptor family in the 1980s. This receptor family is an important drug target that has fueled the successful development of six injectable therapies approved for treatment of multiple sclerosis, ulcerative colitis, Crohn`s disease, plaque psoriasis, acute coronary syndrome and complications during percutaneous coronary intervention.